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Purpose: The anti-tumor activity of glucose analogs 2-deoxy-glucose (2-DG) and D-allose was investigated alone
or in combination with p38 mitogen-activated protein kinase (MAPK) inhibitor SB202190 or platinum analogs as a
strategy to pharmacologically target glycolytic tumor phenotypes.
Methods: Hypoxia inducible factor-1 alpha (HIF-1α) protein accumulation in pancreatic cell lines treated with
SB202190 alone and in combination with glucose analogs was analyzed by Western blot. HIF-1α transcriptional activity
was measured in MIA PaCa-2 cells stably transfected with a hypoxia response element luciferase reporter following
treatment with glucose analogs alone, and in combination with SB202190. Induction of cleaved poly(ADP-ribose)
polymerase (PARP) was measured by Western blot in the MIA PaCa-2 cells. In vitro anti-proliferative activity of 2-DG and
D-allose alone, or in combination with oxaliplatin (pancreatic cell lines), cisplatin (ovarian cell lines), or with SB202190
were investigated using the MTT assay.
Results: SB202190 decreased HIF-1α protein accumulation and transcriptional activity. 2-DG demonstrated greater
anti-proliferative activity than D-allose. Pre-treatment with SB202190 enhanced activity of both 2-DG and D-allose in
MIA PaCa-2, BxPC-3, ASPC-1, and SK-OV-3 cells. The combination of D-allose and platinum agents was additive to
moderately synergistic in all but the OVCAR-3 and HEY cells. SB202190 pre-treatment further enhanced activity of
D-allose and 2-DG with platinum agents in most cell lines investigated.
Conclusions: SB202190 induced sensitization of tumor cells to 2-DG and D-allose may be partially mediated by
inhibition of HIF-1α activity. Combining glucose analogs and p38 MAPK inhibitors with chemotherapy may be an
effective approach to target glycolytic tumor phenotypes.
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Pancreatic cancer and ovarian cancer are aggressive, fre-
quently chemotherapy resistant malignancies character-
ized by a high degree of molecular heterogeneity [1,2].
Both tumor types have been shown to be glycolytically
active as evidenced by nuclear medicine imaging [3,4].
Targeting the metabolic phenotype of these tumors, ra-
ther than a specific genotype, is an attractive therapeutic* Correspondence: abaker@uacc.arizona.edu
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unless otherwise stated.strategy which may help overcome resistance to standard
therapies.
Aerobic glycolysis, often referred to as the Warburg ef-
fect, is the conversion of glucose to lactic acid in the pres-
ence of oxygen and is one of the core hallmarks of both
primary and metastatic cancers [5]. This adaptive meta-
bolic mechanism is associated with a proliferative advan-
tage and is closely linked with tumor invasiveness due to
the increased production of lactic acid in the extracellular
microenvironment [6]. Hypoxia-inducible transcription
factor-1 alpha (HIF-1α) is the primary transcription factor
that regulates the expression of genes essential for glycoly-
sis including glucose transporter 1, hexokinase 1 and 2,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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is continually expressed, but the protein is quickly ubiquiti-
nated and degraded by the proteasome under normoxic
conditions. However, constitutive expression of HIF-1α
protein occurs in some tumor cells due to activation by
growth factors, or mutations in Von-Hippel-Lindau (VHL),
tumor protein 53, or phosphatase and tensin homolog
[reviewed in [7]]. In addition, reactive oxygen species (ROS)
can regulate HIF-1α transcription and translation via the
phosphoinositide 3-kinase/protein kinase B (PI3K/AKT)
and extracellular signal-regulated kinases (ERK) pathways
resulting in HIF-1 α accumulation and transcriptional activ-
ity in normoxia and hypoxia [reviewed in [8]].
Inflammation is another hallmark of cancer and is a
common component of the pancreatic [9,10] and ovar-
ian tumor [11,12] microenvironment that has recently
been shown to have an impact on tumor cell metabol-
ism. Cancer associated fibroblasts in the tumor stroma
secrete pro-inflammatory cytokines such as Tumor Ne-
crosis Factor-alpha and Interleukin-17 that can induce
aerobic glycolysis in adjacent tumor cells via upregula-
tion of transcription factors including HIF-1α, avian
myelocytomatosis virus mammalian homolog, and Nu-
clear Factor Kappa B [13,14]. This effect has been re-
ferred to as “metabolic symbiosis”. The p38 mitogen
activated protein kinase (MAPK) pathway transduces
signals in response to multiple inflammatory mediators
and oxidative stress and has been shown to be a critical
regulator of inflammation-associated tumorigenesis [2].
Nuclear expression of p38 MAPK and ERK 1/2 in pan-
creatic tumors is associated with shorter survival times
[15]. Inhibitors of the p38 MAPK pathway are in pre-
clinical and clinical development for cancer and inflam-
matory diseases [reviewed in [16]]. The biological effects
of p38 MAPK inhibitors are highly tissue, context, and
time dependent [17]. ERK 1/2 and p38 MAPK have both
been implicated in the phosphorylation of HIF-1α
[reviewed in [7]]. In the MIA PaCa-2 pancreatic cell line
p38 MAPK activation in response to ischemia resulted
in phosphorylation of HIF-1α which inhibited binding to
VHL, allowing HIF-1α accumulation [18]. Pharmaco-
logical inhibition of p38 in MIA PaCa-2 cells [18], pul-
monary fibroblasts [19] and chondrocytes [20] has been
shown to abrogate HIF-1α protein expression. Other
studies suggest that p38 MAPK promotes formation of
HIF-1-p300 complex thereby enhancing HIF-1α tran-
scriptional activity [21].
There have been extensive pre-clinical investigations
describing the activity and mechanisms of action of the
synthetic glucose analog 2-deoxy-glucose (2-DG) as an
anti-cancer agent [22]. Clinically, high dose 2-DG is well
tolerated and initial studies suggest it can be safely ad-
ministered in combination with radiation therapy [23].
2-DG competes with glucose for intracellular transportvia the glucose transporter type 1 (GLUT-1) transporter.
In the cell it competes with glucose for hexokinase
mediated phosphorylation to form 2-DG-6-phosphate,
which is not further metabolized to any significant ex-
tent. Multiple mechanisms of action have been proposed
for the anti-tumor activity of 2-DG including inhibition
of glycolysis with resulting decreases in generation of ad-
enosine triphosphate (ATP) and nicotinamide adenine
dinucleotide phosphate and alteration of N-linked glyco-
sylation due to its similarity in structure to mannose. In
vitro, 2-DG treatment results in oxidative stress [24], ac-
tivation of endoplasmic reticulum stress and the un-
folded protein response [25], and induction of apoptosis
and autophagy.
D-allose is a rare sugar with a similar structure to 2-
DG produced from D-ribose for which a recent mass
production process has been developed [26]. D-allose
has been studied in multiple cancer cell line models in-
cluding ovarian cancer and was demonstrated to have
promising anti-tumor proliferation and pro-apoptotic
activity [27]. Interestingly, D-allose has also been dem-
onstrated to have anti-inflammatory and anti-oxidant ef-
fects [28]. The mechanisms of action of D-allose are still
not well understood. Studies in neuroblastoma Neuro2A
cells suggest that D-allose competes with D-glucose
prior to or at the mitochondrial respiratory chain result-
ing in a decrease in D-glucose driven ROS production
and decrease in ATP synthesis [29].
Resistance to 2-DG has been reported to be mediated
by HIF-1α in several cancer cell line models [30]. We
therefore hypothesized that p38 MAPK inhibition may
increase the efficacy of glucose analogs via suppression
of HIF-1α activity. To test this we investigated the activ-
ity of 2-DG and D-allose in combination with SB202190,
a pharmacological p38 MAPK inhibitor, in a panel of
pancreatic and ovarian cancer cell lines. Treatment with
SB202190 caused a modest decrease in HIF-1α protein
and transcriptional activity in the MIA PaCa2 cells and
resulted in enhanced efficacy of both 2-DG and D-allose
together and in combination with oxaliplatin in the ma-
jority of cell lines investigated. Our study suggests that
p38 MAPK inhibition should be investigated further as a




Unless otherwise specified, all biochemicals were pur-
chased from Sigma-Aldrich, St. Louis, Missouri.
Cell culture
MIA PaCa-2, BxPC-3, AsPC-1, OVCAR-3, and SK-OV-3
cells were purchased from American Type Culture Col-
lection (Manassas, VA). The HEY cell line was purchased
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BxPC-3, and AsPC-1 cell lines are pancreatic adenocar-
cinomas. The OVCAR-3, SK-OV-3, and HEY cells are
ovarian adenocarcinomas. Cells were grown at 37°C and
5% CO2. MIA PaCa-2 and HEY cell lines were cultured
in Dulbecco Modified Eagle medium (Cellgro, Manassas,
VA) with 10% fetal bovine serum (Thermo Scientific,
Rockford, IL) and 4.5 g/L glucose. BxPC-3 and AsPC-1
cell lines were cultured in Roswell Park Memorial Insti-
tute medium (RPMI) (Cellgro) with 10% FBS. OVCAR-3
cells were cultured in RPMI (Cellgro) with 15% FBS. SK-
OV-3 were cultured in McCoy’s 5A medium (Cellgro)
with 10% FBS For hypoxia studies, cells were grown in
1% oxygen, in a humidified, 37°C Ruskinn Invivo2 Hyp-
oxia Workstation (Ruskinn, Pencoed, Bridgend, UK).
Cells were tested for mycoplasma contamination using
the MycoAlert mycoplasma detection assay kit from
Lonza (Basal, Switzerland) and found to be negative. To
verify cell line authenticity, genomic DNA was extracted
and diluted appropriately in TE buffer (10 mM Tris-CL,
pH 7.5, 1 mM EDTA), and submitted to the University
of Arizona Genomics Core (Human Origins Gentoyping
Lab) for analysis. Autosomal short tandem repeat (STR)
typing was conducted across the 13 core STRs in Com-
bined DNA Index System and referenced against allelic
peaks in cell lines of previously confirmed genotype. All
cell lines were verified as authentic.
Cell treatments
2-DG and D-allose (Omicron Biochemicals, South Bend,
IN) treatments were performed for the concentrations
and time points indicated for each experiment. For inhib-
ition of p38 MAPK, a 2 hour pretreatment with 20 μM
SB202190 (Calbiochem, San Diego, CA) was performed
and continued through the duration of the experiment.
Oxaliplatin (Sanofi Aventis, Bridgewater, NJ) and cisplatin
treatments were performed at concentrations and time
points indicated both alone and in conjunction with 2-
DG, D-allose, and or SB202190 treatments.
Antibodies for western blot
The following antibodies and concentrations for western
blotting were used: 1:1000 α-Tubulin (Calbiochem, San
Diego, CA), 1:1000 Caspase-3 (Cell Signaling Technology,
Danvers, MA), 1:1000 Cleaved poly(ADP-ribose) polymer-
ase (PARP) (Cell Signaling Technology), 1:500 PARP (BD
Pharmingen, San Jose, CA) and 1:1000 HIF-1α (Santa Cruz,
Dallas, TX). Horseradish peroxidase-conjugated secondary
antibodies for mouse and rabbit were used at a dilution of
1:10,000 (Jackson ImmunoResearch, West Grove, PA).
Lactate assay
Lactate production was analyzed using the L-Lactate Assay
Kit I (Eton Bioscience, San Diego, CA) per manufacturerinstructions. A standard curve was generated using lactate
standards provided in the kit. Lactate concentration of
samples was determined by plotting samples on the stand-
ard curve. Lactate secreted by the cultured cells was deter-
mined by subtracting the lactate concentration of media
alone from the lactate concentration of each sample. Intra-
cellular lactate was normalized to protein concentration of
the sample using the 660 nm Protein Assay kit (Thermo
Scientific).
Development of a stable-expressing HRE-luciferase MIA
PaCa-2 cell line
MIA PaCa-2 cells were stably transfected with a pcDNA3.1
vector expressing luciferase (Invitrogen) controlled by a
hypoxia-response element (HRE) motif from the promoter
of the VEGF gene (obtained from Dr. Robert Gillies, Lee
Moffitt Cancer Center). Transfections were performed
using FuGENE HD Transfection Reagent (Roche, Mann-
heim, Germany) according to manufacturer’s protocol.
Treatments of 1200 μg/ml G418 were added to 10%FBS/
RPMI cell media 24 hours following transfection to select
for stably transfected cells. Fresh media containing anti-
biotic was added every 2–3 days and selection was per-
formed for 20 days. Following selection, stable cells,
defined as HRE-Luc MIA PaCa-2, were pooled based on
their baseline luciferase expression as well as the respon-
siveness of luciferase expression to hypoxia treatments.
The pooled cell line demonstrated a 15 fold elevation of
HRE expression after 24 hours of growth in 1% O2 relative
to cells grown in normoxia for 24 hours (data not shown).
Cells were maintained in media supplemented with
400 μg/ml G418. Prior to experiments, cells were grown in
G418 free media for a minimum of 24 hours.
Transfection and luciferase assay
Cells were cultured in 96-well or 24-well plates and
allowed to reach 80% confluence. Cells were treated with
varying concentrations of 2-DG or D-allose, or SB2
02190 as indicated. Firefly luciferase activity was mea-
sured after the times indicated using the Luciferase Assay
System kit (Promega, Sunnyvale, CA) in a multi-detection
microplate reader (BioTek, Winooski, VT) according to
manufacturer’s instructions. Luciferase readings were nor-
malized to the protein concentration of the sample (μg/
ml) which was determined using the 660 nm Protein
Assay kit (Thermo Scientific). The untreated control
group was set to 100%. Biological replicates of each ex-
periment were performed at least three times.
Q-RT-PCR
Total cellular RNA was extracted using NucleoSpin RNA
II total RNA extraction kit (Macherey-Nagel, Duren,
Germany). cDNA was generated from 0.5 ug of DNase-
free RNA using qScript cDNA Synthesis Kit (Quanta
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structions. Reverse transcription (RT) was performed
using a GeneAmp 7300 sequence detection system (PE
Biosystems, Foster City, CA). Amplification reactions were
set up in a reaction volume of 20 μL by use of the Applied
Biosystems TaqMan Univeral PCR Mastermix (Applied
Biosystems, Branchburg, NJ). PCR primers and TaqMan
probe for LDHA were synthesized and pre-optimized
by Applied Biosystems (Assays on Demand) (Foster City,
CA). Each reaction contained 1× PCR Mastermix,
900 nmol of each primer, and 250 nmol of the Fam probe.
Reverse transcription was done at 48°C for 30 minutes,
samples incubated for 10 minutes at 95°C and then ampli-
fication over 40 cycles at 15 sec at 95°C followed by 1 mi-
nute at 60°C. Values were normalized to RPLPO message
and quantitated using the delta CT method as described
by Perkin-Elmer.
Western blot analysis
Cells were rinsed with cold PBS and harvested in
50 mM Tris HCl (pH 8.0), 150 mM NaCl, 1% Triton X-
100, 2 mM EDTA, 5 mM Na3VO4, 200 μM NaF, 21 μM
leupeptin, 230 nM aprotinin, and 1 mM PMSF. Cell lys-
ate was centrifuged at 10,000 × g for 10 minutes at 4°C.
Protein concentration of the resulting supernatant was de-
termined using a 660 nm Protein Assay kit (Thermo Scien-
tific). Total cell lysate (30 μg) was boiled for 5 minutes and
resolved in acrylamide/bisacrylamide gel by electrophoresis.
Proteins were transferred to a polyvinylidene fluoride
(PVDF) membrane (Millipore, Billerica, MA) or nitrocellu-
lose membrane (Bio-Rad, Hercules, CA). The membrane
was blocked with 5% milk in PBST or TBST and incubated
with primary and secondary antibodies according to manu-
facturer’s recommendations. Reactive bands were visualized
by exposure to film using HyGLO Chemiluminescent HRP
Detection Reagent (Denville Scientific, Metuchen, NJ) or
SuperSignal West Dura Extended Duration Substrate
(Thermo Scientific). Blots were stripped in 0.2 M NaOH
with shaking for 10 minutes at room temperature.
MTT cell proliferation assay
The Thiazolyl Blue Tetrazolium Bromide (MTT) assay
was used to compare cell proliferation rates. Cells were
seeded at a density of 3000 cells/well in a 96-well plate
with outer wells left empty for addition of water. After in-
dicated hours of culture, cells were treated with varying
concentrations of drug. MTT dye (2 mg/ml) was added to
cultures treated as indicated above, and incubated for an
additional 4 hours at 37°C. Formazan crystals were dis-
solved in dimethylsulfoxide (DMSO) for 5 minutes and
the plates were read in a spectrophotometer at 540 nm.
For studies combining 2-DG or D-allose with platinum
analogs, cells were treated with a constant ratio of 2000:1
of each drug, respectively. Results were graphed usingGraphPad Prism software and IC50 values and combination
index values for the IC50 concentrations were calculated
using CalcuSyn (Biosoft, Great Shelford, UK). Each assay
was performed with a minimum of 6 analytical replicates.
Statistical analysis
Results are expressed as mean ± S.D. Statistics were cal-
culated using GraphPad InStat software (La Jolla, CA).
All comparisons to controls were calculated using a one
sample t test. Comparisons between treatment groups
were analyzed using an unpaired t test.
Results
2-DG and D-allose inhibit lactate accumulation
To investigate the effect of 2-DG and D-allose treatment
on lactate accumulation, we measured intracellular lactate
and lactate accumulation in cell culture media in MIA
PaCa-2, BxPC-3 and AsPC-1 pancreatic cells grown in
normoxia for 24 hours and treated with 10 mM 2-DG or
D-allose alone (black bars), or in combination with 20 μM
SB202190 (grey bars) (Figure 1A). In the MIA PaCA-2 cell
line 2-DG and D-allose inhibited extracellular lactate ac-
cumulation in the media, with 2-DG showing the greatest
effect at equalmolar concentrations. SB202190 further re-
duced lactate accumulation in combination with both glu-
cose analogs in the MIA PaCA-2 cell line, but had mixed
effects in the BxPC-3 and AsPC-1 cells. Intracellular lac-
tate levels reflect both production and export of lactate
which is influenced by expression and activity of monocar-
boxylate transporters. There was a trend for decreased
intracellular accumulation of lactate following treatment
with 2-DG and D-allose, with no further decrease in com-
bination with SB202190. However, statistical significance
was only observed in the vehicle control compared to 2-
DG treated cell lines. Together, these results suggest that
similar to 2-DG, D-allose has a moderate impact on cellu-
lar metabolism that is cell line dependent.
SB202190 treatment results in a modest inhibition
of HIF-1α protein accumulation
Because HIF-1α regulates glycolytic activity, we investigated
HIF-1α protein in MIA PaCa-2, BxPC-3, and AsPC-1
grown in normoxia or hypoxia (1% O2) treated with vehicle
alone or SB202190 (Figure 1B). When cell lines were grown
in normoxia, constitutive levels of HIF-1α were observed in
MIA PaCa-2 and BxPC-3 cells but not in AsPC-1 cells.
This observation was consistent with a higher level of lac-
tate produced in normoxia in the MIA PaCa-2 and BxPC-3
compared to the AsPC-1 cells (Figure 1A). After 48 hours
of treatment in normoxia, SB202190 treatment diminished
HIF-1α protein accumulating in MIA PaCA-2 and BxPC-3
cells. When the same cells were grown in hypoxia (1% O2),
the amount of hypoxia-induced HIF-1α was only mildly de-
creased after 48 hours of treatment with SB202190.
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Figure 1 Lactate production and HIF-1α expression in pancreatic cancer cell lines. A). Effect of 2-DG and D-allose alone or in combination
with SB202190 following 24 hours of treatment on lactate production measured in cell culture media or in cells. Values are normalized to total cell
protein. One representative experiment is shown, n = 3. *p < 0.05 B). Western blot of cells grown in normoxia or hypoxia for 24 and 48 hours
treated with SB202190 and analyzed for HIF-1α. Tubulin served as a loading control for protein. HIF-1α band density was quantified using ImageJ
software with normalization to α-Tubulin.
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PaCa2 cells alone and in combination with glucose
analogs
Using MIA PaCa-2 cells stably transfected with a HRE re-
porter, we investigated the ability of 2-DG and D-allose to
decrease HIF-1α transcriptional activity. Although both an-
alogues significantly decreased activity, a greater effect was
observed with D-allose at both 24 and 48 hours comparedto 2-DG following treatment (black bars) (Figure 2A). We
also investigated the ability of SB202190 to modulate HRE
activity (grey bars). A modest but statistically significant
(p < 0.0001) decrease in reporter activity after 24 and
48 hours of treatment was observed. When 2-DG or
D-allose were combined with SB202190, a greater de-
crease in reporter activity was observed at 24 and 48 hours













































































Figure 2 HIF-1α transcriptional activity is modulated by SB202190. A). MIA PaCa-2 cells were stably transfected with a HRE-luciferase
reporter and treated for 3 24, and 48 hours with 2-DG or D-allose alone and in combination with SB202190. Luciferase activity was normalized to
total protein. One representative experiment is shown, n = 3. *Indicates a p < 0.05 relative to vehicle control. X indicates a p < 0.01 relative to SB202190
treated control. B). Effect of glucose analogs alone and in combination with SB202190 after 24 and 48 hours in MIA PaCa-2 cells measured by Western
blot analysis of HIF-1α. Tubulin was used as a loading control. Quantification of HIF-1α band density was performed using ImageJ software with
normalization to α-Tubulin.
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with glucose analogs and SB202190
We investigated whether treatment with glucose ana-
logs alone or in combination with SB202190 resulted in
changes in gene expression of the HIF-1 α regulated
gene LDHA using qRT-PCR (data not shown). SB20
2190 treatment decreased LDHA gene expression in
normoxia and hypoxia, but changes were only statisti-
cally significant under hypoxia conditions (p < 0.05). 2-
DG alone showed similar results, with a small decrease
in normoxia (p > 0.05), but a greater decrease in hyp-
oxia (p < 0.05). D-allose alone did not impact LDHAgene expression. SB202190 abrogated gene expression
of LDHA when combined with 2-DG (p < 0.0001) or
with D-allose (p < 0.05) in hypoxia. A similar trend was
observed in normoxia, but was not significant.
SB202190 inhibits HIF-1α accumulation in MIA PaCa2 cells
in combination with glucose analogs
Using the wild-type MIA PaCa-2 cell line we also inves-
tigated the effect of SB202190 on HIF-1α accumulation
in combination with 2-DG and D-allose after 24 and
48 hours of treatment (Figure 2B). Treatment with 2-DG
and D-allose alone caused a time dependent decrease in
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combination with SB202190. It should be noted that the
decrease in HIF-1α may be an acute effect of treatment
given the prior reports that one mechanism of resistance
to 2-DG is upregulation of HIF-1α [30]. These results
suggest that SB202190 may provide additive or synergis-
tic activity with glucose analog treatment for tumor cells
growing in an oxygenated microenvironment. To investi-
gate this hypothesis, proliferation studies were con-
ducted only in normoxia.
SB202190 enhances 2-DG and D-allose mediated PARP
cleavage
To investigate if p38 MAPK inhibition sensitizes cancer
cells to apoptosis we pre-treated MIA PaCa-2 cells with
SB202190 for 2 hours and then added 10 mM 2-DG or
10 mM D-allose (with no washout of SB202190) for
24 hours. Western blot analysis of whole cell lysates was
performed and the blots probed for cleaved and total
PARP (Figure 3). Cleaved PARP levels, indicative of
apoptosis, were observed in cells treated with both 2-DG
and D-allose, although 2-DG caused greater PARP cleav-
age than D-allose. SB202190 alone also resulted in a
small level of PARP cleavage and enhanced PARP cleav-
age in combination with 2-DG and D-allose. Similar re-
sults were observed at 48 hours (data not shown).
Comparison of anti-proliferative activity of 2-DG
and D-allose
To compare the anti-proliferative activity of 2-DG to D-
allose we used both pancreatic and ovarian cancer cell
line models. Cell lines were treated with increasing doses
of 2-DG or D-allose for 48 hours and analyzed prolifera-
tion using the MTT assay (Figure 4). 2-DG showed
marked anti-proliferative activity with IC50 values ran-
ging between 1.45 to 13.34 mM (Table 1). However, D-
allose did not significantly alter tumor proliferation










Figure 3 SB202190 enhances cleavage of PARP when combined with
treated for 24 hours with 2-DG or D-allose alone or in combination with SB
served as a loading control for protein. Cleaved PARP band density was qu
representative experiment is shown, n = 3.PaCa2 cell line having an IC50 value of 53.25 mM
(Table 2). A study by Siu et al. [27] demonstrated D-
allose had growth inhibitory effects in the OVCAR-3 cell
line (50 mM) after 5 days of treatment. It is possible that
longer treatment duration may result in greater activity,
but due to the fast growth rate of many of the cell lines
in our panel we limited treatment duration to 48 hours.
To investigate whether the combination of 2-DG or D-
allose with platinum analogs was more efficacious than
combination with p38 MAPK inhibition by SB202190, we
performed MTTanalysis of 2-DG and D-allose in combin-
ation with oxaliplatin (in pancreatic cell lines) or cisplatin
(in ovarian cell lines) following treatment for 48 hours
(Figure 4, and Tables 1 and 2). Using the median effect
method as described by T-C Chou and P Talalay [for a re-
cent review of this method the reader is referred to [31]],
we calculated the combination index (CI) at the IC50 value
of each drug using CalcuSyn software (Biosoft, Ferguson,
MO). The addition of 2-DG to platinum agent resulted in
additive to moderate synergy in MIA PaCA-2 (CI 0.796),
BxPC-3 (CI = 0.896), AsPC-1 (CI = 0.954), and SK-OV-3
(CI = 0.764). The addition of D-allose to platinum agent
also resulted in additive to moderate synergy in the MIA
PaCa-2 (CI = 0.696), BxPC-3 (CI = 0.787), and SK-OV-3
(CI = 0.857) cells. The ASPC-1 cells, which are inherently
resistant to oxaliplatin and remained inherently resistant to
both compounds with IC50 values being above feasible dose
concentrations. Because SB202190 was kept at a constant
dose during cell treatments, combination indices were not
calculated. Overall, we observed greater growth inhibition
when 2-DG or D-allose was combined with SB202190 than
when combined with platinum compounds.
SB202190 sensitizes cell lines to treatment with 2-DG
and D-allose
To investigate the impact of p38 inhibition on 2-DG and
D-allose anti-proliferative activity, we pre-treated cells
for 2 hours with 20 μM SB202190 and then added 2-DG+ +- +- -
- ++ -- -
+ -- -- +
glucose analogs. Western blot analysis of whole cell lysates from cells
202190. Lysates were probed for cleaved and total PARP. Tubulin










































































































Figure 4 Effect of dosing regimens on the proliferation of pancreatic and ovarian cell lines following 48 hours of treatment. Cells were
treated with increasing doses of 2-DG or D-allose alone or in combination with oxaliplatin (pancreatic cell lines), cisplatin (ovarian cell lines) and/
or SB202190. Cell proliferation was measured using the MTT assay. The ratio of 2-DG or D-allose to the platinum analogs was 2000:1 for all doses,
respectively. One representative experiment is shown, n = 6.
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ment with 20 μM SB202190 alone for 50 hours did not
cause significant inhibition of cell proliferation (the %
change in absorbance values of treated compared tovehicle control ranged from 71.69 to 97.18%; (data not
shown). The combination of 2-DG and SB202190 re-
sulted in a decreased IC50 value for all cell lines investi-
gated except OVCAR-3 cells. BxPC-3 cells showed the











2-DG + 20 μM SB202190 +
Platinum
2-DG (mM) Platinum (μM) CI at IC50 2-DG (mM) Platinum (μM)
MIA PaCa-2 1.45 3.37 0.95 0.48 0.796 0.48 19.72 0.24 0.12
BxPC-3 10.80 28.13 8.12 4.06 0.896 0.60 32.50 1.23 0.61
ASPC-1 11.47 >50 10.55 5.25 0.954 4.90 >50 5.77 2.88
OVCAR-3 3.39 6.93 3.39 1.69 1.243 3.9 26.45 4.1 2.05
HEY 10.17 32.90 9.88 4.94 1.122 2.63 50> 2.44 1.22
SK-OV-3 13.34 11.53 6.46 3.23 0.764 1.42 21.05 2.01 1.01
IC50 values represent the level of drug that inhibited cell growth by 50% following 48 hours of treatment. Combination index (CI) values are defined as: <0.1 =
very strong synergy, 0.1-0.3 = strong synergism, 0.3-0.7 = synergism, 0.7 – 0.85 = moderate synergism, 0.85-0.9 = slight synergism, 0.9-1.1 = nearly additive,
1.1-1.45 slight to moderate antagonism.
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value dropping from <10.8 mM to 0.60 mM. The com-
bination of D-allose and SB202190 resulted in enhanced
anti-proliferative activity in the MIA PaCa2, BxPC-3 and
SK-OV-3 cell lines, with IC50 values <11 mM.
SB202190 is antagonistic with platinum compounds
alone, but enhance anti-proliferative activity when
combined with platinum plus glucose analogs
We also investigated the activity of platinum com-
pounds in combination with SB202190 (Figure 4,
Tables 1 and 2). We observed combined treatment
with SB202190 and platinum agents resulted in re-
duced anti-proliferative activity, with markedly higher
(2 fold or higher) IC50 values in both pancreatic and
ovarian cancer cell lines. However, when cells were
pre-treated with SB202190 followed by addition of
platinum agent and 2-DG, enhanced anti-proliferative
activity was observed for all cell lines investigated, in-
cluding the AsPC-1 cell line which was highly resist-
ant to oxaliplatin monotherapy. Pre-treatment with
SB202190 followed by addition of platinum and D-
allose also resulted in decreased IC50 values in MIA
PaCa-2, BxPC-3, and SK-OV-3 cell lines.Table 2 Anti-proliferative activity (IC50 values) of D-allose alo
SB202190
D-allose + Platinum
Cell line D-allose (mM) Platinum (μM) D-allose (mM) Platinum (μ
MIA PaCa-2 53.25 3.37 4.16 0.95
BxPC-3 >100 28.13 43.3 21.65
ASPC-1 >100 >50 >100 >50
OVCAR-3 >100 6.93 15.84 7.92
HEY >100 32.90 52.68 26.34
SK-OV-3 >100 11.53 18.55 9.27
IC50 values represent the level of drug that inhibited cell growth by 50% following
very strong synergy, 0.1-0.3 = strong synergism, 0.3-0.7 = synergism, 0.7 – 0.85 = m
1.1-1.45 slight to moderate antagonism.Discussion
Pancreatic cancer and ovarian cancer are both lethal dis-
eases that are molecularly complex. Clinical results with
molecularly targeted agents in these malignancies have in
general been disappointing and current treatment strat-
egies still rely heavily on chemotherapy and radiation.
Gemcitabine remains the first line standard of care in pan-
creatic cancer and cisplatin/taxol is one of the primary
standard of care treatments for ovarian cancer. Oxaliplatin
is used as second line treatment in combination with a
fluoropyrimidine (5-FU/leucovorin or capecitabine) in pa-
tients with advanced or metastatic pancreatic cancer who
have good performance status [32]. New treatment strat-
egies are needed that can be safely combined with chemo-
therapy and/ or radiation to overcome resistance.
Aerobic glycolysis is a hallmark of tumor cells result-
ing in the conversion of pyruvic acid to lactic acid in ox-
ygenated conditions. Lactic acid is rapidly exported from
cells by monocarboxylate transporters to maintain a
neutral intracellular pH [33]. Thus, accumulation of
extracellular lactate is correlated with metabolic activity.
Targeting these tumor phenotypes that are glycolytically
active using the glucose analog 2-DG has been exten-
sively investigated pre-clinically in a wide variety ofne and in combination with platinum analogs and/or
D-allose + 20 μM
SB202190 (mM)
D-allose + 20 μM SB202190 +
Platinum
M) CI at IC50 D-allose (mM) Platinum (μM)
0.696 3.18 1.98 0.99
0.787 4.09 8.75 4.38
n/c 74.11 >100 >50
1.171 >100 51.7 25.85
1.002 94.17 53.01 26.5
0.857 10.82 9.74 4.87
48 hours of treatment. Combination index (CI) values are defined as: <0.1 =
oderate synergism, 0.85-0.9 = slight synergism, 0.9-1.1 = nearly additive,
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demonstrate marked differences in response to glucose
analog treatment across cell lines. This may be a par-
tially due to differences in proliferation rates of the cells
(for example MIA PaCa-2 cells grow faster than BxPC-3 or
AsPC-1 cells). However, proliferation rate is not the only
factor influencing sensitivity to glucose analogs as demon-
strated by the HEY ovarian cancer cell line which grows
much faster than the OVCAR-3 cells, but had a higher
IC50 value at 48 hours (10.17 vs 3.39 mM, respectively).
2-DG is clinically well tolerated [24], suggesting that
pre-clinical findings with standard of care chemotherapy
could be translated to the clinic. Preclinical studies have
shown enhanced anti-tumor activity in pancreatic
models with a variety of drugs including gemcitabine
[34]. Cisplatin has demonstrated enhanced cytotoxicity
in combination with 2-DG in head and neck cancer cells
and in lung cancer cell lines [35,36]. Cisplatin-resistant
cancer cell lines with decreased hexokinase levels have
been shown to be more sensitive to the combined activ-
ity of cisplatin with 2-DG or 2-fluorodeoxyglucose [31].
Our results also demonstrate enhanced anti-tumor activ-
ity of 2-DG in combination with cisplatin in ovarian can-
cer cell lines and oxaliplatin in pancreatic cancer cell
lines. However, we did not investigate the correlation of
hexokinase activity with this effect. HIF-1α is often asso-
ciated with resistance to chemotherapy including oxali-
platin [37] and cisplatin [38], and has also been shown
to mediate resistance to 2-DG [29]. Pancreatic and ovar-
ian cancers have high expression of HIF-1α [39,40]. Acti-
vation of the p38 MAPK pathway has been associated
with cisplatin resistance, although the effect of p38
MAPK inhibition is highly variable across cell lines [41].
Our studies demonstrated enhanced anti-proliferative
activity in some cell lines when glucose and platinum
analogs were combined with a p38 MAPK inhibitor.
This combined activity may be partially due to abroga-
tion of HIF-1α transcriptional activity mediated by p38
MAPK inhibition. However, further mechanistic studies
are warranted to fully understand the context in which
p38 MAPK may be beneficial in combination with glu-
cose analogs.
The tumor microenvironment is characterized not
only by low oxygen levels, but oxidative conditions and
inflammation which can all contribute to activation of
the p38 MAPK signaling pathway. The p38 MAPK path-
way is involved in many cellular functions including pro-
liferation, cellular differentiation, and apoptosis. It has
also been linked with DNA repair and regulation of p-
glycoprotein. The level and extent of p38 MAPK signal
in addition to the molecular context of expression are all
important in determining the function of p38 MAPK
[17]. Our results suggest that p38 MAPK inhibition in
glycolytically active tumors expressing high levels ofHIF-1α, or in oxidized cells with increased HIF-1α activ-
ity should be further studied. However, it should be ap-
preciated that given the many biological roles of p38
MAPK there are probably multiple mechanisms by
which p38 MAPK inhibitors may modulate response to
drug therapy in addition to HIF-1α regulation. It should
also be noted that in situations where cell proliferation is
regulated through growth factor signaling via the PI3K/
AKT pathway as opposed to stress signaling via ROS, in-
hibition of the p38 MAPK may have little therapeutic
benefit as recently shown in a study by Cheng et al. [42].
D-allose has shown promising anti-proliferative and
pro-apoptotic activity in other cancer cell line models,
but to our knowledge the anti-tumor activity of D-allose
has not been studied in pancreatic cancer models. In the
current study we observed moderate single agent D-
allose anti-proliferative activity in the MIA PaCa-2 cell
line and promising synergistic activity with oxaliplatin in
MIA PaCa-2, BxPC-3, and SK-OV-3 cell lines. Similarly,
D-allose had anti-proliferative activity in these same cells
lines when pre-treated with SB202190. Notably, the MIA
PaCa-2 and BxPC-3 cell lines accumulate greater extracel-
lular lactate than the AsPC-1 cell line that was resistant to
D-allose monotherapy or combined drug treatments. Inter-
estingly, D-allose resulted in greater inhibition of HRE-
luciferase activation compared to 2-DG although it was
less potent at inhibiting cell proliferation. Together, these
observations suggest that D-allose may have distinct mech-
anistic differences as compared to 2-DG.
Cisplatin is associated with a high incidence of
nephrotoxicity. D-allose has been shown to inhibit the
production of inflammatory mediators of nephrotox-
icity including TNF-alpha and renal monocyte chemo-
attractant protein-1 and to protect against cisplatin
induced renal tubular injury in mice [43]. Our results
demonstrate that D-allose does not inhibit the anti-
proliferative activity of oxaliplatin or cisplatin, and even
enhances platinum mediated anti-proliferative activity
in selected cell lines. Therefore, D-allose may not only
act as a chemosesitizer but also have renal protective
effects in combination with cisplatin.Conclusions
Tumor cells develop multiple adaptive survival mecha-
nisms including metabolic adaptations. Combination can-
cer therapies that target cancer metabolism via modulation
of HIF-1α are attractive due to the central role HIF-1α
plays in cancer metabolism and drug resistance. Our
studies provide the rationale to investigate glucose ana-
logs, which target metabolism, in combination with p38
MAPK inhibitors, which modulate HIF-1α. However,
the combination of only p38 MAPK inhibitors with
platinum agents should be conducted with caution.
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